Background: Administering extracorporeal membrane oxygenation (ECMO) to critically ill patients with acute respiratory distress syndrome has substantially increased over the last decade, however administering ECMO to patients with hematologic malignancies may carry a particularly high risk. Here, we report the clinical outcomes of patients with hematologic malignancies and severe acute respiratory failure who were treated with ECMO. Methods: We performed a retrospective review of the medical records of patients with hematologic malignancies and severe acute respiratory failure who were treated with ECMO at the medical intensive care unit of a tertiary referral hospital between March 2010 and April 2015. Results: A total of 15 patients (9 men; median age 45 years) with hematologic malignancies and severe acute respiratory failure received ECMO therapy during the study period. The median values of the Acute Physiology and Chronic Health Evaluation II score, Murray Lung Injury Score, and Respiratory Extracorporeal Membrane Oxygenation Survival Prediction Score were 29, 3.3, and -2, respectively. Seven patients received venovenous ECMO, whereas 8 patients received venoarterial ECMO. The median ECMO duration was 2 days. Successful weaning of ECMO was achieved in 3 patients. Hemorrhage complications developed in 4 patients (1 pulmonary hemorrhage, 1 intracranial hemorrhage, and 2 cases of gastrointestinal bleeding). The longest period of patient survival was 59 days after ECMO initiation. No significant differences in survival were noted between venovenous and venoarterial ECMO groups (10.0 vs. 10.5 days; p = 0.56). Conclusions: Patients with hematologic malignancies and severe acute respiratory failure demonstrate poor outcomes after ECMO treatment. Careful and appropriate selection of candidates for ECMO in these patients is necessary.
Introduction
Patients with hematologic malignancies are susceptible to infection because they have an immunocompromised status due to the disease process or chemotherapy. In particular, pneumonia and acute respiratory failure (ARF) are the most life-threatening complications, and these complications are the main reason for admitting patients with hematologic malignancies to the intensive care unit (ICU). [1, 2] Despite notable advances in oxygen therapy such as highflow nasal cannulas [3] and non-invasive ventilation, [4] cc This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/ licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. 
Results
During the study period, a total of 15 patients received ECMO treatment. Nine of these patients were men, and the median age was 45 years (31-54 years). The individual characteristics of the study population are provided in Table 1 . The etiology of ARF was viral or bacterial pneumonia in all patients. All patients also fulfilled the criteria of severe ARDS.
1) Hematologic malignancies
The types of hematological malignancies in our current study population included the fol- 13) who was diagnosed with acute myeloid leukemia being transformed from myelodysplasia syndrome because ARF occurred immediately after diagnosis.
2) Baseline characteristics
Immediately before ECMO support, the median Table 2 ).
3) ECMO treatment
ECMO treatment was initiated at the decision of the treating intensivist. The duration of mechanical ventilation prior to ECMO initiation was < 2 days in 11 patients, 2-7 days in 2 patients, and > 7 days in 1 patient. There 3) in 10 patients. There were no arterial blood gas data at 24 hours after ECMO initiation in 5 patients because they died within 24 hours.
4) Adverse events
There were hemorrhage complications in 4 patients.
Major bleeding occurred in 2 patients. These complications included diffuse alveolar hemorrhage (patient no. 1) ischemia (patient no. 14).
5) ICU and hospital outcome
Of the 3 patients with successful ECMO weaning, only 1 patient (patient no. 14) was transferred to the general ward at 10 days after ECMO initiation. The median survival period was 10 days (Fig. 1) . The longest survival 
Discussion
Despite recent improvements in the outcomes of critically ill patients with hematologic malignancies, their survival rates still remain poor. [6] Thus, ECMO could be proposed as the ultimate therapy. Previous studies on this issue were mainly focused on pediatric patients [21] [22] [23] because ECMO is established as the standard therapy for neonates and children with ARF that is refractory to conventional management strategies. [24] In this study, patients with solid tumors. Moreover, the different outcomes in these reports might not be due to the lack of experience using ECMO because our hospital is a tertiary referral hospital that treats many ECMO patients (> 100 cases/year). In our current study series, more patients who received HSCT (n = 10) than in other studies, and pneumonia and ARF occurred during cytopenia immediately after high-dose chemotherapy (n = 6). The median absolute neutrophil count of the patients who received
HSCT within 90 days (6 patients) was 0.0 (range 0-0.5) × 10 3 /μL. These severe impairment of immunity would contribute poor control of infection. There was even one case of graft failure (patient no. 5) and a patient whose malignancy relapsed at several months after HSCT (patient no. 2). Furthermore, there was a patient who received over 7 days of ventilation (patient no. 7) and a patient who did not received chemotherapy for malignancy (patient no. 13). Hence, the survival was poor among our RESP scores of our current study population, these were very poor and the majority of the patients were below group IV. The RESP scores did not correlated with the survival time, but most of our patients with a RESP score below group IV died within 7 days. The RESP score consists of 12 variables and includes the acute respiratory diagnosis group, immunocompromised status, and other variables that are determined before ECMO initiation. [20] Basically, it is difficult for patients with hematological malignancy and pneumonia to exceed a RESP score of 1 (i.e., group III) since the presence of immunocompromised status and viral/bacterial pneumonia result in score -2 and 3, respectively. Therefore, the early application of mechanical ventilation (score 3 for < 48 hours, or score 1 for 48 hours to 7 days) and the use of neuromuscular blockade (score 1) before ECMO initiation is needed to increase the RESP score in such patients and, if possible, in young patients (score 0 for 18-49 years) who are expected to receive ECMO treatment.
Bleeding events were observed in 4 patients (27%) in our study. Among these cases, major bleeding was noted in 2 patients. This value is relatively lower than reported by Wohlfarth et al.
[15] Bleeding remains a clinically significant issue despite the evolution in ECMO devices such as hollow-fiber oxygenators, centrifugal pumps and bicaval dual-lumen cannulas over several decades. [7, 24] Although the incidence of complications in our present Our study had several limitations of note. First, this was a retrospective study with a small number of patients.
However, it would be nearly impossible to perform a randomized prospective study since there are considerable medical and ethical issues. Second, all of the patients in our current study had poor baseline characteristics including poor hematologic disease status, APACHE II score, LIS, and RESP score, which led to rescue therapy.
Third, they were only a very small portion of patients among critically ill patients with hematologic malignancies who underwent respiratory failure during the study period. Therefore, the outcomes of our study cannot be generalized since the patients were from a highly select group.
In conclusion, patients with hematologic malignan- 
